February 5, 2015
G1 Therapeutics Raises $33 Million in Series B Financing
RESEARCH TRIANGLE PARK, N.C., Feb. 5, 2015 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in oncology, today announced the completion of a $33 million Series B financing round. Lead investors Eshelman Ventures and RA Capital Management were joined by new investors Lumira Capital and Boxer Capital of Tavistock Life Sciences, as well as the company’s existing investors Hatteras Venture Partners, MedImmune Ventures, and Mountain Group Capital.
February 2, 2015
G1 Therapeutics to Present at 17th Annual BIO CEO & Investor Conference
RESEARCH TRIANGLE PARK, N.C., Feb. 2, 2015 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in oncology, today announced that Chief Executive Officer Mark Velleca, MD, PhD, will provide a corporate overview at the 17th Annual BIO CEO & Investor Conference. The presentation will take place on Monday, February 9 at 9:45 a.m. ET at the Waldorf Astoria in New York City.